Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4080 Synchronous case of advanced gastric Her-2 + adenocarcinoma and metastatic neuroendocrine neoplasm of unknown origin – A MiNEN case?

Introduction: Gastric adenocarcinoma case treated with capecitabine and trastuzumab. After surgery, a G2 neuroendocrine tumor was found.

Conference:

Presenting Author:

Authors: Jimenez Gordo A, Gomez Raposo C, Garcia-Sancho Tellez L, Salinas Moreno S, Madrid Vallenilla A,

Keywords: MiNEN, clonal selection, citostatic treatment,

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3922 National registry of pheochromocytomas and paragangliomas in the Colombian territory: Epidemiological insights and clinical profiles

Introduction: Limited epidemiological data exist concerning pheochromocytomas and sympathetic paragangliomas (PPGL) in Latin America, resulting in a reliance on small cohorts and case reports that may not accurately represent the true behavior of these tumors in the population.

Conference:

Presenting Author: Zea Lopera J

Authors: Zea Lopera J, Agredo Delgado V, Román González A, Donado Gómez J, Jiménez C,

Keywords: Pheochromocytoma, paraganglioma, PPGL, neuroendocrine tumor, incidentaloma, clinical presentation,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,

#3781 Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,